A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability and Pharmacokinetics of LML134 in Healthy Volunteers

Trial Profile

A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability and Pharmacokinetics of LML134 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs LML 134 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors Novartis
  • Most Recent Events

    • 24 Apr 2016 Status changed from recruiting to completed.
    • 15 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 15 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top